Big Biotech Movers: IBB, MNKD, BLUE, FLDM, and AQXP

Biotechs are having another bad day, as evidenced by the iShares Nasdaq Biotechnology ETF's (IBB) sharp drop

Aug 7, 2015 at 12:51 PM
facebook X logo linkedin

U.S. benchmarks are trading are lower today, as traders weigh the latest nonfarm payrolls report against the possibility of a September interest-rate hike. Additionally, a continued sell-off in biotechs -- as evidenced by a more than 2% plunge in the iShares Nasdaq Biotechnology ETF (IBB) --  is pressuring the Nasdaq Composite (COMP) to another loss, with the benchmark off nearly 0.9% at last check.

Put players are turning in a quick response to IBB's drop, with volume running at three times what's typically seen at this point in the day. Eleventh-hour speculators betting on even more losses through tonight's close appear to be buying to open the weekly 8/7 360-strike puts, while traders with a slightly longer-term -- and more bearish -- outlook are purchasing new positions at IBB's weekly 8/14 355-strike put. At last check, the exchange-traded fund was lingering near $362.50.

Drilling down on specific equities, MannKind Corporation (NASDAQ:MNKD) is off 1.5% at $4, extending its analyst-induced week-to-date decline to 6.8%. This volatile price action could continue next week, when MNKD joins a number of other notable names in the earnings confessional.

bluebird bio Inc (NASDAQ:BLUE), meanwhile, has plunged more than 16% to $131.65. Sending the shares to their lowest point since early May is a wider-than-expected second-quarter loss and revenue miss. The security is now in danger of closing south of its 140-day moving average for the first time since May 2014.

Having its worst day ever -- literally -- is Fluidigm Corporation (NASDAQ:FLDM), with the stock off 37% at $12.53, and fresh off a record low of $10.90. The company turned in lower-than-expected second-quarter sales, and downwardly revised its full-year revenue forecast, prompting a downgrade to "neutral" at Piper Jaffray, and price-target cuts from Mizuho (to $15), Cowen and Company (to $15), and Leerink (to $28).

On the other end of the spectrum is Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), which has surged nearly fourfold to $6.91, after the firm yesterday announced positive mid-stage trial results for its bladder pain treatment. Additionally, AQXP said its second-quarter loss was less than Wall Street was expecting. The stock is now in the green on a year-to-date basis, and has effectively filled its early July bear gap.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI